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Abstract  
The reasons why teenagers and young adults with cancer do, or do not, participate in clinical 
trials is not wholly understood. We explored the perceptions and experiences of young people 
with bone cancer, and health professionals involved in their care, with regard to participation 
in two clinical trials. We conducted semi-structured interviews using narrative inquiry with 
twenty-one young people aged 15 to 24 years and eighteen health professionals. New 
understandings emerged about perceptions of, and factors that influence participation in, 
clinical trials. These include perceptions about the importance and design of the clinical trial, 
communicating with young people in an age-specific manner, using language young people 
are comfortable with, support from family and peers and specialists in teenage and young 
adult cancer .care. We conclude that addressing these factors may increase acceptability of 
clinical trials and the trial design for teenagers and young adults with cancer and ultimately 
improve their participation.  Qualitative research has an important place in the development, 
review and evaluation of clinical trials in ensuring trials are patient centred, and are 
acceptable and appropriate for teenagers and young adults. 
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Introduction 
Recruitment to cancer clinical trials is recognised as an indicator of quality care and 
considered good practice. Clinical trials allow rigorous testing of new treatments with the 
possibility to impact on improvements in survival for successive generations of cancer 
patients. Children’s cancer care, where five-year survival rates have improved from around 
40% in the 1970s to almost 80% for those diagnosed today (Smith et al., 2010), is a notable 
trial success story largely ascribed to high levels of participation in clinical trials. In England, 
inclusion of cancer patients in a clinical trial is advocated by health care policy (Department 
of Health, 2007) and is underpinned by policy specific to children and young people 
(National Institute for Clinical Excellence, 2005). A number of countries, including the 
United Kingdom (UK), have reported under-representation of teenagers and young adults 
(TYA) in cancer clinical trials, when compared to children or older adults. Some researchers 
have suggested this is associated with lesser survival gains for TYA (Bleyer, 2005; Ferrari 
and Bleyer, 2007). 
The perceived benefit of a clinical trial has been found to positively influence the 
decision of 12 to 22 year olds and their parents to participate (Read et al., 2009), and the 
perceived burden of adolescents being asked to participate in a trial soon after a cancer 
diagnosis has also been reported (Broome et al., 2001). Life stage transition across 
adolescence and young adulthood (Erikson, 1995; Havighurst, 1972) accompanied by care 
being delivered across children’s and adult’s health care settings (Bleyer, 2007) are also 
reported as factors affecting trial participation in TYA. Quantitative research investigating the 
role of health professionals in TYA cancer trial participation has previously highlighted the 
role of organisational factors, for example  increased participation in care settings where 
children’s cancer trial protocols are offered compared to care settings where they are not 
(Parsons et al., 2011; Shochat et al., 2001); and the administrative burden of treating a patient 
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on a clinical trial (Benjamin et al., 2000). The clinical trial participation of TYA was also 
found to be negatively influenced by clinicians preference for treatment protocol over the 
clinical trial (Benjamin et al., 2000; Shaw and Ritchey, 2007).  
Interest in TYA with cancer  regarding clinical trial participation has recently gained 
momentum. Barakat et al. (2014) set out to understand decision making patterns of 13 young 
people using semistructured interviews with TYA, parents and health professionals; together 
with evaluating the Pediatric Research Participation Questionnaire (PRPQ). Barakat et al. 
(2014) reported that young people were not fully involved in decision-making, and suggested 
that stress, illness and immaturity impaired this. A process to enhance collaborative decision-
making through structured diagnostic meetings was recommended. Following development 
of some questionnaire items, further exploration and validation, they suggest the PRPQ may 
help address barriers and benefits to trial participation.  
Attitudes about clinical trial participation among 15 - 39 year old survivors of 
lymphoma and leukaemia, and a healthy college sample, were identified using an Attitude 
Towards Cancer Trial Scales (Grigsby et al., 2014).  Fourteen were recruited who had cancer 
and were offered a clinical trial, of which eight participated. Grigsby et al. (2014) reported a 
positive attitude towards clinical trials; however they also suggested that attitudes to TYA 
participation were not well understood and might impact on trial participation. They 
highlighted the need for exploratory work to further understand the complexities of personal, 
structural and contextual issues that affect cancer trial participation. This echoes 
recommendations of key authors about adult cancer clinical trials, where they emphasize the 
importance of qualitative interviews to understand experience (Cox, 1998) and to explore 
decision making (Cox and Avis, 1996).  Understanding patient and professional perceptions 
of trial entry, along with trial protocol characteristics, have been identified as key to 
successful accrual (Maslin-Prothero, 2006; Cox and McGarry, 2003).  
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Although there is growing interest in initiatives to increase enrolment of TYA into 
clinical studies (Weiss et al. 2015), a continuing gap in our understanding of the perceptions 
and experiences of TYA participating in cancer clinical trials, may continue to hinder 
progress. We therefore sought to make a further contribution to the emerging evidence by 
seeking to expand our understanding of the perceptions and experiences of both TYAs and 
health professionals. To do this, we focused on two clinical trials for bone cancer: 
EURAMOS-1 (E-1) and Euro- Ewings-99 (E-99). Bone cancer has a peak incidence in this 
age group, and unlike other cancer types has had less improvement in survival (Bleyer, 
2006). The five-year survival rate is 50-60% (Whelan et al., 2012), emphasising the need for 
further developments in treatment. In recent years, multinational groups have established 
large, collaborative, research projects to focus on bone sarcomas by undertaking clinical trials 
across multiple countries, which is a necessity given the rarity of these cancers (Whelan et 
al., 2015).  These trials had ‘appropriate’ age eligibility criteria, including the 15 - 24 age 
range; however despite the appropriate age eligibility criteria, deficits in accrual of young 
adults to these clinical trials had still been observed. This suggests factors other than 
permissive age eligibility are involved (Fern et al., 2014). 
Both of these trials were long and complex with a staged consent process; this 
involved consenting to register on the trial very soon after diagnosis and consenting to 
randomized treatment after three to four months of chemotherapy. During this initial 
treatment period, very intense, standard chemotherapy was administered. This usually 
required extensive periods of hospitalisation, and caused significant side effects with some 
young people developing complications requiring intensive care or dose limitation. Surgery, 
which was sometimes extensive and involved amputation of limbs, followed this first course 
of chemotherapy. Radiotherapy was an additional requirement for many patients with Ewing 
sarcoma. Consent to treatment randomisation occurred shortly after surgery and pathological 
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staging of the disease. Randomised treatment varied in intensity and duration for example, it 
could involve a further eighteen months of treatment or high-dose chemotherapy (a simplified 
flow diagram of the stages of the trials is shown in Fig.1). 
The primary aim of this study was to explore the perception of teenagers, young 
adults and professionals in participating in bone cancer clinical trials using narrative 
interviews. To gain a comprehensive, in-depth understanding we gathered data from all 
stakeholders involved: potential trial participants, recruiting professionals and those who care 
for young people treated as part of the two clinical trials described. We hoped to gain a   
deeper understanding of the issues, experiences and perspectives of the stakeholders; identify 
factors important in trial design; understand the processes and contexts of recruitment; and 
ultimately contribute to strategies to increase enrolment to clinical studies for TYA. 
 
Methods 
Design 
A philosophy of interpretive interactionism that supports the study of meaning, which is 
grounded in the lives of individuals, was adopted for this study (Schwandt, 2000). We 
conducted interpretive qualitative interviews using narrative methods with all those involved 
in these two clinical trials. This was to explain and explore the ‘whats’ and ‘hows’ of 
personal stories to reveal how the meaning of trial participation is constructed over time 
(Sparkes, 2005). Focussing on both teenage and young adults, and health professionals, 
allowed for data to be triangulated, attempting to obtain a much deeper and broader 
understanding of the complexities of recruiting to and participating in these bone cancer 
clinical trials (Denzin, 1978; Flick, 1998). 
Narrative was used as a method to re-present experience (expressing and 
reconstituting it) (Squire, 2008). Reissman (2008) suggests narrative encompasses extended 
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accounts of lives in contexts that develop over the course of single interviews or therapeutic 
conversations. In this study, narrative allowed the young people and health professionals to 
have a voice and facilitated the telling of the experience of participating in a clinical trial, the 
span of which extended over time. 
 
Sample and Setting  
We recruited participants with primary bone cancer aged 15 - 24 years at diagnosis from a 
single, principal TYA treatment centre in the UK. The age range is defined as TYA according 
to the epidemiological age criteria used in England (NICE, 2005, p13). The setting was a 
well-developed bone and soft tissue sarcoma centre.  
After discussion with the clinical team, we invited all TYA within this age range at 
diagnosis, and eligible to participate in E1 and EE99 between January 2009 and September 
2011, to participate in this study. No TYA were excluded if they fitted these criteria. Twenty-
one of thirty-four eligible young people agreed to participate. The TYAs were between six 
and thirty-two months from diagnosis at the time of interview, the age range was 15-25 years, 
with a median of 20 years; and fourteen were male. Seven of the young people had Ewing’s 
sarcoma, and were invited to participate in the EE-99 trial; the remaining 14 had 
osteosarcoma and were invited to participate in the E-1 trial. Nineteen registered on the trials, 
of those, twelve were eligible for randomized treatment, of which six consented. No TYAs 
consented to randomized treatment for the EE-99 trial.  
We purposefully sampled professionals involved in the recruitment and care of TYA 
eligible for these trials. The care of TYAs in this principal treatment centre is undertaken 
across children’s and adult oncology services and health professionals were sampled to 
reflect this service configuration. Professional participants included those directly involved in 
recruiting TYA into the clinical trials and supporting them during decision-making about 
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clinical trial participation (including medical oncologists, registrars, clinical nurse specialists 
and research nurses); and those involved in the care of the TYAs when they were receiving 
treatment in the clinical trial (including chemotherapy nurses, ambulatory care and oncology 
ward managers, pharmacists and orthopaedic surgeons). Eighteen, of a total twenty-nine, 
health professionals invited agreed to participate. Nine professionals were directly involved 
in recruitment to the two bone cancer trials and nine professional were involved in the care of 
the TYAs receiving treatment in the trials.  
 
Ethics and Consent 
We obtained approval from a National Health Service research ethics committee (study 
reference: 11/LO/0523). It is worth noting in England that at sixteen a young person is 
presumed to have capacity to consent to their own treatment (NHS Choices, 2014). We 
therefore sent letters inviting young people, or their parent if less than 16 years, to directly 
contact the research team if they wished to opt out and not receive further information. 
Young people were sent further information about the study and were later contacted by 
telephone. We e-mailed invitations to professionals, followed by a telephone call. For those 
potential participants wanting to participate in our research, we obtained written, informed 
consent, and assent and parental consent from those less than 16 years old. We assured all 
participants of anonymity, and that participation would remain confidential and that they 
could withdraw from the study at any time. 
 
Methods of Data Collection 
We used semi-structured narrative interviews to capture the perceptions and experience of all 
participants. AB conducted interviews using a collaborative, co-participatory process 
(Fontana and Frey, 2000); providing an opportunity for participants to speak freely of their 
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experience.  An experienced TYA qualitative health researcher SP, supported AB in 
conducting the interviews. We initially asked the young person to tell their story from when 
they first heard about the clinical trial, after diagnosis, and then used the questions in a 
narrative structured interview style to focus on the chronology of events. 
We identified open questions and probes from the literature (Lavender V, Watson E,  
Phillips R and Boulton M, Unpublished). We used reflective probes to paraphrase, encourage 
depth and demonstrate active listening to facilitate participants to tell their story (Wengraf, 
2001). Some examples of probes included 'Can you tell me more about that?’ and ’How did 
that make you feel?' (See Table 1 and Table 2).  Prior to data collection we refined the 
interview schedule with two young people with cancer from the research reference group. 
Interviews lasted on average 50 minutes. With permission, we digitally recorded and 
transcribed interviews. Parents, other family members, or friends were present during seven 
of the young peoples’ interviews. Parents actively took part and answered questions in three 
interviews.  
 
 Data Analysis 
We analysed transcripts using an interpretative approach similar to that described by 
(Charmaz, 2000). This included memoing the transcripts, coding and constantly comparing 
codes to identify categories and themes. We continued this analysis until we had developed 
an emergent theoretical framework (Charmaz, 2000). We analysed data from TYA and health 
professional interviews separately. SP and AB read and coded all the transcripts. FG and VL 
coded a sample of transcripts to validate the coding process. To manage such large volumes 
of data we began the process of developing an analytical framework following the first 
interview and through a process of ongoing review and assimilation developed a framework 
from the additional transcripts and their categories and themes. 
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After the analytical frameworks were developed, SP and VL returned to the coded 
transcripts of all the interviews ensuring that nothing had been missed, adding another layer 
of rigour and review to the process. SP and VL then integrated themes and subcategories of 
the two analytical frameworks into an integrated analytical framework from both health 
professional and young person data. This allowed us to follow a thread and actively seek out 
similarities and differences within, and between, the two data sets (Moran-Ellis et al., 2006). 
SP and VL used the integrated analytical framework to synthesise key findings of TYA 
participation in the bone cancer clinical trials. 
 
Results 
We identified the following influencing factors across both data sets: perceptions and 
understanding of clinical trials, communication and information, support and coping, and the 
context of clinical trials and the culture of TYA specialist care. The influence of these factors 
on weighing up the benefits and burdens of clinical trial participation were most evident at 
critical time points of the young person’s treatment experience. Participants’ narratives 
highlighted the criticality of registration and randomization, and to some degree the young 
people reflected on their experience over time. Time and the timing of events seemed 
significant to all those who participated in the study. We present a balance of interweaved 
quotes from young people and health professionals and a diagrammatic representation of the 
findings concludes our paper. 
 
Influencing Factors 
Perception of Clinical Trials 
Some TYA had learnt about clinical trials in science lessons at school; however for most their 
knowledge was related either to information given by health professionals or their personal 
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cancer experience. Some perceived clinical trials as synonymous with chemotherapy; others 
regarded it as an alternative treatment option. One participant suggested that, “It’s just 
another way of helping, find different ways to actually cure it faster and get people healthier 
quicker.  So I think when I hear it, it’s like another help, like a helpful organisation.” Some 
young people who had registered on the clinical trial, did not perceive receiving standard 
treatment following registration as a clinical trial and instead thought of the clinical trial as 
being something that happened at, or after, randomisation when trial treatment arms differed: 
I didn’t really think about it . . . Like it [being on a trial] only would have made a 
difference if I’d got to randomisation and they said, “You’re on the one that takes a 
month longer.”  I would, you know, it would just be, “no way”. 
Clinical trials were commonly described as being an experiment, with some TYAs 
describing ‘feeling like a guinea pig’. This was not necessarily perceived negatively, but it 
was unnerving for some. Terminology used by health professionals may have influenced this 
perception. One professional discussed the importance of using the term ‘study’ because they 
thought ‘trial’ sounded experimental and affected patients’ perceptions. This highlights the 
health professionals’ insight into the possible ways in which terminology might be interpreted 
by young people. Use of the term ‘rarer cancer’ highlighted the small number of people with 
this type of tumour and heightened the young person’s sense that every person counted. 
Young people talked about being aware of the importance of participation in clinical trials: 
“It’s such a rare thing; they’re really desperate for people to do it.” This understanding 
probably stemmed from conversations with health professionals, and could be perceived as 
an additional pressure by the young person. Professionals highlighted the uniqueness of the 
young person’s diagnosis and the importance of clinical trials. One professional said:  
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I would start off by saying that, you know, this is a rare cancer that, you know, we 
know a lot about how to treat it, and we know that because of all the clinical trials that 
have been done in the past. 
The possibility of improving the outcome of the disease for themselves, and the 
perceived benefit of helping others, outweighed the burden of participation for many of the 
young people:  
If it’s a little bit of information for the doctors to work out why it happens, then  
hopefully it will stop people having cancer, in the future or just create awareness, I  
don’t know . . . I just hope there are benefits for everyone really. 
Professionals strongly emphasized the fundamental importance of clinical trials in 
bone and soft tissue cancer and for TYA where there has been little improvement in 
outcomes. The perception that clinical trials are vital for improving survival resulted in an 
emotive response in some professionals. “I wish we had a trial for every patient who, that we 
would treat… And so I feel frustrated or a failure in a way that we do not have any more, we 
don’t have enough clinical trials open.”  
 
Communication and Information 
Communication and information, together with support and coping, were central to the 
experience of trial participation particularly at the times of registration and randomisation. 
Effective face–to-face communication and information provision was perceived as central for 
both TYAs and professionals. Face-to-face communication was discussed by the young 
people as being TYA-centred, reflecting the philosophy of TYA cancer care in the research 
setting. Professionals spoke about the value of working in a TYA care setting, where there 
was expertise in talking to young people. One TYA stated, “They didn’t talk to me like I was 
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a child.  They spoke to me as if it was my decision, it’s my life, it’s up to me.” Written 
information was discussed as useful when the young people felt unwell, but they also 
discussed the fact that they might not feel up to reading. “I might have looked at [the 
information] for two minutes and thought, Oh I can’t read it now, they can do what they want 
to do.” 
The language used in the communication with professionals was emphasised. 
Interpretation of the meaning of ‘experiment’, ‘trial’ and ‘rare cancer’ has already been 
highlighted. One young person found the use of the word ‘cancer’ difficult; and ‘poor 
response’ used at the time of randomisation provoked a strong, negative reaction in two 
participants. One participant stated, “Oh for God’s sake, I’m not a poor responder, I don’t 
want to be a poor responder.” Another was surprised at this choice of wording:  
Do you have to call it a ‘poor response’? . . .  I’ve gone through so many of the kind  
of forms of, “How are you feeling, what emotions do you have?” And it is really 
carefully tailored in terms of wording and things like that. And then you have poor 
response.  It’s just something so small can have such a big effect. 
 
Health professionals involved in recruitment of young people to the clinical trials used 
the term ‘poor response’ during their interviews as part of their everyday discourse about the 
clinical trial, and although they expressed anxiety about what the term meant in relation to 
tumour response, they did not express anxiety about using the term ‘poor response’ in 
relation to trial participation.  
Enabling trust and building rapport over time, was identified by both TYAs and health 
professionals, as an important basis to facilitate good communication and ultimately trial 
decision-making. This was expressed by the young people, “They made you feel really 
comfortable, they made you feel like at home sort of thing,” and by professionals, “It’s about 
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developing the trust . . . between you and the patient. The more time and opportunities you 
have to do that, is good.” Some professionals were mindful of potential ethical implications 
of having a close rapport with a patient and then asking them to participate in research. One 
professional felt, “If you have a good relationship with a patient and you’ve known them over 
a number of months, then they may sort of subconsciously want to please you and want to do 
what they think you want them to do.” 
Having the opportunity to ask questions was at the core of effective information 
giving and communication. Professionals spoke about the role of asking questions to be able 
to ascertain that young people had a full comprehension of the trial and its implications. For 
young people asking questions facilitated empowerment. “I think the, for me the knowledge 
was what gave me power and gave me confidence in making decisions and if I didn’t know 
something, I would ask, they encouraged my questioning.”  
All participants perceived dialogue between health professionals and young people 
was important. The clinical nurse specialist (CNS) role was particularly highly valued by 
both TYA and other health professionals for their role in communication, information giving, 
support and coping. One professional stated, “The CNS was the person that I feel is almost 
like an unbiased party that they can then ask any questions.” Young people discussed how the 
CNS was able to provide much valued neutrality. It enabled them to work through concerns 
face-to-face, to simplify the information imparted by professionals, and be an ongoing source 
of support, “The CNS becomes like your friend, to be honest with you throughout all of this.” 
 
Support and Coping 
The support of family, peers, and health professionals was fundamental to young people in 
being able to comprehend their diagnosis and treatment and cope with decision-making and 
the treatment experience. For a small number decision-making was family-centred. One 
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young person described it as, “The family having cancer, the family had osteosarcoma.” 
Many professionals discussed family dynamics and the individuality of how families 
function. Family-centred decision-making was not attributed by professionals to the age of 
the young person, but more cognitive ability, emotional maturity, the family dynamic, and the 
young person’s role within the family. For most TYA, the family and others supported 
decision-making. One young person discussed support in regard to processing information:  
Sometimes the words and the terminology that was used was a bit complex, so it was  
a bit lost in translation!  But I think after my mum and dad had explained it to me,  
because they understood, then it helped me a lot to make more decisions.  
 
Having autonomy in decision-making was crucial for most TYA, “It was my choice.  
I’m not 16, it’s not meant to be my choice, but it was my choice and no matter what I chose, 
my parents would stick with me.” For another young person, “I mean, yes you can have 
advice, advice from someone, but at the end of the day you live and die by your own 
decisions.” A desire of the young person to protect their parents, by not putting them in a 
situation where they might feel blamed later, was also recounted:  
I would not deem to put the pressure on my parents at all. And I would not put them  
in a position. You’d be so upset if it was all starting to fall to pieces and you’d be like,  
“You made me want to go on this clinical trial,” you know. 
 
Sometimes there were differences in views about participation in the clinical trial 
between the TYA and parents. One professional recounted a difficult experience when one 
patient at randomisation had said they were doing it because of parental pressure. One young 
person in our research expressed regret about not participating because of a parents influence:  
I said to my dad “I want to do it,” my dad said “What if you do it and get more sick?  
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You need to make things easier for yourself.”  And then, so yes that’s why I said no to  
that trial. 
 
Young people, talked at length about the importance of hearing and sharing stories 
with peers who had similar experiences. There was a desire for a ‘buddy’ who was ‘a few 
steps ahead’ to inspire and give hope to a young person. One young person reflected, “If 
somebody was to tell me that things would have got better and things get easier, I would have 
stayed on the trial. But nobody told me that.” Health professionals completely understood the 
role of peer support, but for them it also raised concerns, “If something goes poorly for 
somebody, they also hear that.” Nevertheless sharing their stories and experiences with 
others, and being able to support others, helped the participants know they were not alone and 
gave them a sense of feeling valued. One TYA described helping the mother of another 
young person with cancer, “She was really worried because he [her son] was so sick and I 
explained to her that’s how I was. She said that I was like a guardian angel.” 
 
Context of Care 
All the TYA in this study emphasized the importance of being treated in a specialist care 
setting. Many were treated on a designated young persons’ unit with peers, where there was 
also access to a wider psychosocial team. This, together with the specialist TYA skills and 
experience of the health professionals, was central to the experience of young people in this 
research. 
One of the reasons that I’m here [being interviewed about participating in a bone 
cancer clinical trial] today, one of the reasons that I was able to get through the 
 19 
treatment with the disposition that I had . . ., was because I was surrounded by people 
of my own age that I could talk to, that I could help and they could help me. That the 
nurses and the doctors knew how to talk to me. 
 
Professionals placed high value on working within an organization that prioritized and 
supported clinical trials.  
So, we are prepared to put in the legwork to, you know, to recruit patients.  But part of  
that legwork is about the fact that it will add to your consultation time and you will  
need more than one consultation. . . . I think if you’ve got a big, well-resourced unit,  
then you are going to be able to put young people into trials.  
 
Working within a team to provide timely support and information; feeling supported 
themselves by the team; and developing communication skills as a team were discussed in 
depth. Professional and organizational factors, such as team working and efficient 
infrastructure, were perceived by the health professionals as facilitating a culture that was 
conducive for the participation of TYA in bone cancer trials.  
 
Critical Time Points 
Registering on a Clinical Trial  
Young people were typically registered on the trials within two weeks of receiving their 
cancer diagnosis, with discussions starting from the point of diagnosis. The timing of this was 
difficult for all young people. One young person described their thoughts about this, “Oh this 
is another decision I’ve got to make, you know, I don’t really want to – I’m not interested. … 
Why give someone this kind of decision when all this is going on already.” Young people 
who had experienced a prolonged diagnostic journey felt a sense of urgency to start 
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treatment. Pressure from the professionals to commence treatment was also experienced. One 
young person explained, “I was quite rushed into it.  But that was only because they wanted 
to start my treatment really straightaway.”  
Ensuring that information was shared and understood, and consent was informed at 
this time, was perceived by some professional groups, such as research nurses, as difficult for 
both TYA and themselves professionally. One health care professional expressed, “I think a 
lot of the time it’s just too much information to take in.  And I think the ones that turn it 
down, it is just too much.” Others, particularly medical professionals, directly responsible for 
obtaining consent, perceived registration as easier than randomisation. At registration they 
were explaining the opportunity to register on a trial initially with standard treatment and opt 
out at a later date. Some TYA decided to register for the trial at this stage for this reason, 
“We can make the decision to drop out. But we can’t make a decision to drop in. So leave all 
doors available, all options open.” For others there was a strong sense of wanting to 
participate. Either to get better, “[I] just wanted to be well. I think even if I didn’t understand, 
I would accept … I didn’t want to have this pain again,” or to help others, “If I can be part of 
a trial and make something, find a better way for people to be treated or an easier way to be 
treated, I don’t mind being that guinea pig.”  
 
Professionals also recognised altruism as a motivating factor, “Generally the people 
are quite interested in taking part in research to help, to help other patients in the future 
really, if not for themselves.” The timing of conversations was crucial; professionals 
recognised individual’s distress at receiving a cancer diagnosis and during the registration 
process they consistently emphasized the importance of giving young people sufficient time 
and plenty of opportunities for communication, information and support. 
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Randomisation 
Randomisation was expressed by most TYA and health professionals as the point when 
critical decisions were made. Consent to randomisation for both trials took place following 
surgery. Eligibility to the treatment arm of the clinical trials depended on treatment response. 
One professional explained, “If the patient had a poor response that is going to be a harder 
conversation to have.” 
This professional went on to explain the irony that although the good response 
conversation was the easiest to have, TYAs whose disease had responded well were often 
happier to stay with standard treatment and were less keen to be randomised. For many it was 
not an easy decision. One TYA described the anguish:  
It was like, “you’ve had a poor histological response. And like what do you want to  
[do]?” I couldn’t make my mind up at the time, because in my head I had four months  
more left of treatment and I was looking at this longer one, it was like double the  
time.  And more drugs as well. I was like, “oh my God, I don’t know”. . . . I stood  
outside by the lifts and I was just thinking like, “oh my God what am I going to do?”  
 
Some TYAs found the concept of randomisation and the concept of clinical equipoise 
difficult to comprehend. Being asked to make a (sometimes difficult) decision about 
receiving the treatment arm, when it was ultimately dependent upon a random computerised 
event took time for some young people to make sense of: "I wanted to go on the trial, so the 
randomisation was a bit of a pointless thing to me, but then at the end of the day it gives 
everyone a chance to be on the trial". 
Others described how they would have felt disappointed if they had not received the 
experimental treatment arm, or would have preferred the professionals to make a decision for 
them. Despite the desire for control over choice of a treatment arm, both TYA and health 
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professionals felt that the young people had better comprehension of what was involved, what 
treatment was like, and that decision-making and randomisation, if not easy, was more 
informed.  
The decision-making process at randomisation involved weighing up the benefits and 
burdens of the treatment (See Fig. 2). Extended periods of hospitalisation were perceived as 
an unacceptable burden for many young people. Many needed to stay in hospital between 
chemotherapy treatments because of toxicities, which considerably limited the amount of 
time they were at home, “If you can imagine that four out of the five weeks I was in hospital, 
and even when I wasn’t in hospital, I felt I had a massive hangover from the worst night out 
you’ve probably ever had.”  
Toxicity from the treatment was very powerfully described by many young people. A 
number were treated in intensive care units for treatment-related toxicity and a few had 
treatment toxicities that were dose-limiting or resulted in treatment cessation. The 
burdensome nature of treatment for bone sarcomas was fully understood and appreciated by 
the health professionals: 
You know, they’re probably some of the hardest chemotherapy regimens that I’ve  
ever worked with – that in itself without adding extra ten weeks or a couple of months  
to their sort of treatment time you know with some of them they are kind of, “Okay  
I’ve had enough”. 
 
Most young people expressed a desire to return to a normal life. One reflected how 
the sense of lost time is perhaps more acute for a younger person, when so much [change] is 
happening, than an older person. She said:  
I can’t see there’s an easy way to entice a young person into a clinical trial, because a  
young person is still young. If I was 50 then I probably would have done it, you know,  
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probably it wouldn’t bother you to have that extra time. But for someone who is  
growing up fast, life’s too short. 
  
 
Discussion 
This is the first qualitative study that integrates data from TYAs with cancer and health 
professionals involved in their care, about recruitment to, and participation in clinical trials. 
Similar to other reports, our findings illustrate the multi-factorial nature of the experience of 
participating in clinical trials together with the ongoing decision-making process (Biedrzycki, 
2010). We identified influencing factors and critical time points for young people eligible to 
participate in these two clinical trials (See Fig. 2).  
The time of clinical trial registration soon after diagnosis when there was an 
imperative to start treatment urgently, was felt by many TYA and health professionals to be 
challenging; this is similar to other findings (Broome et al., 2001). In addition, consultations 
about consenting to randomised treatment coincided with difficult discussions about 
treatment response, although there was a sense that having experienced treatment the young 
people were more informed.  
We found that the prospect of prolonged treatment duration or increased treatment 
intensity on the experimental treatment arm often influenced the decision to participate. 
Adolescence and young adulthood compounded the sense of intensity and longevity of 
treatment for many TYA; they expressed urgency ‘to get on with life’ and referred to the 
poignancy of ‘wasted time’.  
Previous research with TYA highlights the importance of perceived benefits of 
participating in research to self (Broome et al., 2001) and others (Hendricks-Ferguson et al., 
2013), as central in decision-making.  In this study benefit to self carries special meaning in 
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the context of cancer clinical trials, where treatments may have significant adverse effects 
and survival is dependent on treatment effectiveness. Altruism was expressed as a reason to 
participate in both the bone cancer clinical trial and our research. The benefit for others often 
outweighed the burdens of trial participation for the young people. 
Young people valued being placed at the centre of communication, which supported 
autonomous decision-making and reflected a highly-evolved model of multidisciplinary TYA 
cancer care (Kelly et al., 2004). Our findings contrast with findings reported by (Barakat et 
al., 2014) that TYA perceived low involvement in making decisions about clinical trial 
participation. The young peoples’ accounts of language and communication used by 
professionals, suggests that both written and verbal communication are important influencers 
on their perception of clinical trials. 
The value of the CNS as a support mechanism was evident and should be considered 
in strategies to enhance trial participation. The CNS was perceived by both young people and 
professionals as an essential party, being regarded as a ‘neutral friend’; trust, support and 
rapport developed over time with other staff including key medical staff was also highly 
valued.  These relational aspects of care could, however, have the potential to generate 
conflicts of interest when obtaining clinical trial consent. It is essential for health 
professionals to work within ethical frameworks and develop high levels of awareness and 
reflexivity within themselves and across teams (Finlay and Gough, 2003).   
Our findings also illustrate the importance of support from, and support for, peers 
participating in the same clinical trial. Peer support is an aspect of care that is central to 
specialist TYA cancer care philosophy (Tai et al., 2014).  
 
Reflections on the study: strengths and limitations 
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Using a narrative approach facilitated the young people to reflect on their experience over 
time. The stories shared in this study highlighted that the young people perceived the clinical 
trial as their treatment, rather than part of their treatment. Some young people expressed 
regret about not choosing to enter the randomised phase of the trial. The psychological effects 
of decision-making in terms of regret and guilt have been found in other studies (Biedrzycki, 
2010; Stevens and Ahmedzai, 2004). For others, participating in the clinical trial and/ or 
having chemotherapy treatment marked a poignant period in their life story and participating 
in our research provided an opportunity for reflection. Some young people were still in one of 
the two clinical trials, some were two years after treatment. Of these a few were struggling to 
cope with life after cancer treatment. Two TYA had relapsed and one was receiving palliative 
treatment. These different time periods from data collection to when the TYA participated in 
the trials is a limitation of this research. Prospective longitudinal research, such as that by 
Stevens and Ahmedzai (2004), would  allow the  exploration of experience over time.  
Parents were present in some interviews. Although not actively encouraged, this could 
be seen as a reflection of the model of TYA cancer care, communicating with TYA within 
the context of the whole family, and the reality for professionals in clinical trial recruitment. 
The researcher who conducted the interviews, similar to the health professionals recruited to 
this research, kept the young person at the centre and prioritised their autonomy. However, 
there was flexibility to individual needs and dynamics and occasionally the parent took a 
participatory role in the conversational-style interview.  
Using a narrative approach provided the participants of this study with an equal voice. 
Our findings reinforce the importance of hearing the perspective of both the young people 
and the health professionals who managed their care. Triangulating the data by integrating 
data sets from young people and health professional’s added rigour to our study design, in 
addition to credibility, dependability and depth of the findings. The analysis was conducted 
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by four members of the research team, none of whom had involvement with the clinical team, 
which added further dependability and trustworthiness to our findings.  
The setting for this study was a well-developed specialist TYA cancer centre, and thus 
had well-established multidisciplinary teams, focusing on treatment, trials, and psychosocial 
and developmental aspects of TYA cancer care. It is important to acknowledge the different 
contexts in which young people with cancer are cared for, although TYA with bone cancer 
would usually be treated in similar contexts in the UK. Recruiting participants from one 
hospital, together with using an opt-out recruitment process to promote autonomous decision-
making and minimise potential gate-keeping (LeBlanc et al., 2013), might have aided 
recruitment to our research.   
 
Implications for research 
 
Fern et al. (2014) suggest an increase in TYA participation between 2005 and 2010 
can be attributed to five key criteria, the five A’s: Availability, Accessibility, Awareness, 
Appropriateness and Acceptability.  They describe barriers and facilitators including: 
awareness of trials by both patients and health professionals; availability of open studies that 
TYA are eligible for; accessibility of the trial; appropriate trial design with age eligibly 
criteria that is permissive of inclusion of young people; and the acceptability of trial design 
for both patients and health professionals. Our study reinforces key messages in this 
publication and strengthens the call for the involvement of young people and indeed 
professionals in trial design at the outset. The National Institute for Health Research (NIHR, 
2015) suggest that one method to do this is to involve patients as members of the research 
study group. However, there is concern that patient and public engagement in research, for 
example attending research advisory board meetings to discuss acceptability of the design of 
research studies, can be tokenistic and better methods of engaging stakeholders in research 
are still needed (Domecq et al., 2014).  
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 The use of qualitative research to engage stakeholders early in trial design is 
recommended by Barakat et al. (2014) and Woolfall et al. (2014). Our study demonstrates 
use of qualitative research before or alongside clinical trials is central to developing a deeper 
understanding of the acceptability of a clinical trial based on stakeholder perspectives and 
experiences.  
 
Concluding thoughts 
 
This qualitative study provides a deeper understanding of the perceptions and 
experiences of key stakeholders in TYA cancer trials. It has identified factors important in 
trial design and as such contributes to an increasing awareness of the importance of both 
processes and contexts of recruitment to both trial design and treatment delivery. Our, study 
also emphasises a role for qualitative research in clinical trials, from early stages of trial 
design to ongoing evaluation and review, to ensure trials are patient centred. We hope these 
findings alongside further research will ultimately contribute to strategies that increase 
enrolment and retention to clinical studies for TYA, with our primary aim being to improve 
young peoples' outcomes from cancer that we know are influenced by participation in clinical 
trials. 
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Table 1. Examples TYA Interview Questions 
 
Question Area Examples of Questions 
Background Can you tell me a bit about yourself? 
Can you tell me a bit about what is going on with you now? 
Can you tell me about the treatment you have had? 
Knowledge of clinical 
trials 
Can you tell me what you understand about the term clinical trials? 
What do you think about them? 
Registering on a 
clinical trial 
Do you remember being asked to take part in the clinical trial? 
Can you tell me a bit more about this, such as who you were with and 
how long was it since your diagnosis when you were asked?  
Do you remember who you spoke to about it? 
How did you feel about being asked to make that decision? 
What did you decide to do? 
What did you find helpful/ unhelpful? 
Randomization on  
the  clinical trial (for 
those who were 
eligible) 
Was there anything different about deciding to being randomized from 
the time of registration? 
Can you tell me what happened, what you decided and how? 
 
Time of potential 
randomization for all 
What was happening for you at this time? 
How did you feel about the trial/ treatment and things in general at his 
time? 
How have been things since? 
Reflecting back 
 
Reflecting back what, if anything, could have been differently?  
What was particularly helpful? 
What do you think could help young people?  
What advice would you give them? 
What advice would you give professionals? 
Overall what are your thoughts and feelings of clinical trials and your 
experience of them now? 
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Table 2. Examples of Health Professional Interview Questions 
Question Area  Example of Questions  
Background Can you tell me a little bit about your role (in the care of patients with 
bone cancers/ soft tissue tumours)? 
What involvement do you have with the bone sarcoma clinical trials?  
How long have you been involved with these trials/ caring for people 
undergoing these trials? 
Knowledge of 
clinical trials 
What do you understand about clinical trials in general? 
What are your thoughts about treating patients on clinical trials?  
TYA and bone 
cancer trials 
What do you think are the specific issues around recruiting young people 
(15-24 year olds) with cancer to clinical trials? 
What is your understanding of the bone cancer specific trials, Euramos-1 
and EE-99? 
What do you perceive are factors that influence participation in Euramos-
1 and EE-99 for TYA?  
Process of 
recruitment and 
randomization 
(for those 
involved) 
Can you tell me about how TYA patients are recruited to the bone 
sarcoma clinical trials? 
Can you tell me what you discuss when talking to young people or their 
parents, about consenting to the clinical trials? 
What happens at randomization? 
What support is there for patients making decisions about entering these 
clinical trials? 
How do you feel about discussing randomisation? 
How is discussing randomisation different from registration and the initial 
consultation?  
Reflections What sorts of things do you think (would) help support young people 
through the clinical trial? 
 What do you think might support the professionals involved in this 
process? 
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Legend for Figure 1 Twenty-one teenagers and young adults aged 15 – 24 were eligible to 
participate in either the Euro Ewing-99 or Euramos-1 clinical trials. The simplified design of 
the clinical trial is shown in treatment stages. The number of young people that consented to 
each stage of these two clinical trials are shown in brackets. 
 
Legend for Figure 2 Critical time points were experienced at times of consent decisions 
about clinical trial registration and randomisation. Young people on both clinical trials 
received treatment between the times of registration and randomisation, which was an 
influencing factor on consenting to randomised treatment. Perceptions of clinical trials, 
communication and information, support and coping, and the culture of TYA cancer care, 
were found to be influencing factors on weighing up the benefit and burden to participating in 
the clinical trial.  
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Figure 1. Treatment received by young people recruited to this study 
Eligible for randomized treatment 
Registered (n = 13)  Not registered (n = 1) 
No (n = 2) 
Yes (n = 6) No (n = 5) 
Consent to randomized treatment 
Pre-operative chemotherapy (12 weeks) 
Total  
n = 21 (7 female: 14 male)   
n = 7 (3 females: 4 males) with Ewing sarcoma  n = 14 (4 females: 10 males) with osteosarcoma  
Surgery 
Pathology: good or poor tumour response 
Yes (n = 11) 
Randomly allocated treatment 
Dependent on tumour response 
Good response: additional 4 
months of chemotherapy or 
additional 4 months 
chemotherapy, plus additional18 
months weekly interferon 
injections 
Poor response: additional 4 
months chemotherapy or 
additional 7 months 
chemotherapy 
Eligible for 
randomized 
treatment 
Registered (n = 6)  Not registered (n = 1) 
Yes (n = 0) No (n = 1) 
Consent to randomized treatment 
Pre-operative chemotherapy (12 weeks) 
+/- radiotherapy 
 
Surgery 
Randomly allocated treatment  
Additional 4 - 5 months chemotherapy or 
high-dose chemotherapy 
+/- radiotherapy 
+/- peripheral blood stem cell transplant 
Evaluate 
Pre-operative chemotherapy 
(6 weeks) plus radiotherapy 
(n = 5) 
Pre-operative chemotherapy 
(6 weeks) (n = 1) 
Adjuvant chemotherapy 
(~ 6 months)  
+/- radiotherapy 
Surgery 
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Figure 2. Diagrammatic representation of influencing factors and critical time points in 
TYA bone cancer clinical trial participation 
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